Aortic StenosisRESTORENCT06777368
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
An observational study of Aortic Stenosis, run by Medtronic Cardiovascular at 71 sites in United States.
Trial summary
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR). Read more about this study
- Who is it for?
- Ages 18 to 105 years
- Conditions the study is for
- Aortic Stenosis
- What is being tested?
- Medtronic TAV and Edwards TAV
- Type of treatment
- Medical device
- How many people
- 225 participants
- Where
- 71 sitesUnited States
- Study dates
- 6 Feb 2025to Nov 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 105 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population includes patients with symptomatic heart disease due to BVF affecting TAVs and requiring redo TAVR.
Who may be able to join
- BVF of a TAV (either Medtronic or Edwards) requiring redo TAVR
Who cannot join
- BVF due solely to paravalvular regurgitation
- Active endocarditis
- Untreated acute valve thrombosis
- Life-expectancy less than 1-year
- Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable
- Participating in another study that may influence the outcome of this study
Trial locations and contacts
71 sites in 1 country. Contact the study team or a site near you to ask about taking part.
71 sites in 1 country
United States71 sites, 70 recruiting
- Recruiting
Lehigh Valley Hospital
Allentown, Pennsylvania, 18103
Traci Eichelberger
Dzanan Ramic, MD
- Recruiting
University of Michigan Health
Ann Arbor, Michigan, 48109
Jessica Frizzell
Stanley Chetcuti, MD
- Recruiting
Ascension Seton Medical Center Austin
Austin, Texas, 78705
Madeline Gleason
Mark Pirwitz, MD
- Recruiting
Heart Hospital of Austin
Austin, Texas, 78705
Alana Rice
Frank Zidar, MD
- Recruiting
Medstar Union Memorial Hospital
Baltimore, Maryland, 21218
Keith Moyer
John Wang, MD
- Recruiting
The Johns Hopkins Hospital
Baltimore, Maryland, 21287
Michele Fisher
Rani Hasan, MD
- Recruiting
University of Alabama at Birmingham
Birmingham, Alabama, 35233
Marissa Waite
Mustafa Ahmed, MD
- Recruiting
Massachusetts General Hospital
Boston, Massachusetts, 02114
Joanna Mandinova
Rahul Sakhuja, MD
- Recruiting
Brigham and Women's Hospital
Boston, Massachusetts, 02135
Sinead Coyle
Piotr Sobieszczyk, MD
- Recruiting
Buffalo General Medical Center
Buffalo, New York, 14203
Lindsay Moshides
Vijay Iyer, MD
- Recruiting
University of Vermont Medical Center
Burlington, Vermont, 05401
Amy Henderson
Harold Dauerman, MD
- Recruiting
University of Virginia Medical Center
Charlottesville, Virginia, 22908
Erin Orr
John Saxon, MD
- Recruiting
The Christ Hospital
Cincinnati, Ohio, 45219
Amanda Sears
Puvi Seshiah, MD
- Recruiting
Morton Plant Hospital
Clearwater, Florida, 33756
Sue Fisher
Joshua Rovin, MD
- Recruiting
University Hospitals of Cleveland Medical Center
Cleveland, Ohio, 44106
Nisreen Zueiter
Guilherme Attizzani, MD
- Recruiting
OhioHealth Riverside Methodist Hospital
Columbus, Ohio, 43214
Kailee Brooks
Laura Flannery, MD
- Recruiting
MercyOne Iowa Heart Center
Des Moines, Iowa, 50314
Kendra Tuttle
David McAllister, MD
- Recruiting
Henry Ford Hospital
Detroit, Michigan, 48202
Emily Ward
Pedro Engel Gonzalez, MD
- Recruiting
Inova Fairfax Hospital
Falls Church, Virginia, 22042
Diana McLean
Matthew Sherwood, MD
- Recruiting
HealthPark Medical Center, Lee Memorial Health
Fort Myers, Florida, 33908
Michelle Deckard
David Cervantes, MD
- Recruiting
Parkview Health
Fort Wayne, Indiana, 46845
Tressa Brunner
Roy Robertson, MD
- Recruiting
Corewell Health (Spectrum)
Grand Rapids, Michigan, 49503
Elizabeth Helm
William Merhi, MD
- Recruiting
Hartford Hospital
Hartford, Connecticut, 06106
Jadwiga Jerman
Sarfaraz Memon, MD
- Recruiting
Baylor Saint Luke's (The Texas Heart Institute)
Houston, Texas, 77030
Sylvia Carranza
Guilerme Silva, MD
- Recruiting
Houston Methodist Hospital
Houston, Texas, 77030
Tia McGaughy
Sachin Goel, MD
- Recruiting
University of Texas Health Science Center at Houston
Houston, Texas, 77479
Matthew Franciskovich
Abhijeet Dhoble, MD
- Recruiting
Saint Vincent Heart Center of Indiana
Indianapolis, Indiana, 46290
Cari Fekete
Ezequiel Munoz, MD
- Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
Amy Black
Amy Olinger
- Recruiting
The University of Kansas
Kansas City, Kansas, 66103
Amy Gorsuch
George (Trip) Zorn, MD
- Recruiting
St. Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Peggy Owen
Chetan Huded, MD
- Recruiting
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Brian Aldrich
Michael Young, MD
- Recruiting
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027
Jaclyn Cordova
Somjot Brar, MD
- Recruiting
Medical Center of the Rockies
Loveland, Colorado, 80538
Darcee Robeson
Justin Strote, MD
- Recruiting
Catholic Medical Center
Manchester, New Hampshire, 03102
Jennifer Driscoll
Fahad Gilani, MD
- Recruiting
Northwell Health
Manhasset, New York, 11030
Kristine McGowan
Bruce Rutkin, MD
- Recruiting
UPMC Pinnacle
Mechanicsburg, Pennsylvania, 17050
Olivia Vehabovic
Hemal Gada
- Recruiting
Aurora St. Lukes Medical Center
Milwaukee, Wisconsin, 53215
Reva Matz
Tanvir Bajwa, MD
- Recruiting
Froedtert Hospital
Milwaukee, Wisconsin, 53226
Amy Blair
Saif Anwaruddin, MD
- Recruiting
Abbott Northwestern/Minneapolis Heart
Minneapolis, Minnesota, 55407
Alexa Hunsinger
Paul Sorajja, MD
- Recruiting
Providence Saint Patrick Hospital
Missoula, Montana, 59802
Tara Westlie
Michael Reed, MD
- Recruiting
TriStar Centennial Medical Center
Nashville, Tennessee, 37203
Anna Grace Monroe
Andrew Goodman, MD
- Recruiting
St. Thomas West Hospital
Nashville, Tennessee, 37205
Gabriel Bryant
Michael Andrew Morse, MD
- Recruiting
Jersey Shore University Medical Center
Neptune City, New Jersey, 07753
Ann Marie DeToro
Matthew Saybolt, MD
- Recruiting
Yale New Haven Hospital
New Haven, Connecticut, 05610
Scott Ardito
John Forrest, MD
- Recruiting
NYU Langone Medical Center
New York, New York, 10016
Patricia Kozikowski
Mathew Williams, MD
- Recruiting
Mount Sinai Hospital
New York, New York, 10029
Mercedes Morales Castro
Samin Sharma, MD
- Recruiting
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
Christine Calayo
Matthew Summers, MD
- Recruiting
Oklahoma Heart Hospital
Oklahoma City, Oklahoma, 73120
Debbie Schommer
Mohammad Ghani, MD
- Recruiting
Orlando Health/Orlando Regional Medical Center
Orlando, Florida, 32806
George Ngo
Joel Garcia-Fernandez, MD
- Recruiting
The Valley Hospital
Paramus, New Jersey, 07652
Kimberly Michel
Rajiv Tayal, MD
- Recruiting
Abrazo Arizona Heart Hospital
Phoenix, Arizona, 85016
Jessica Byrne
Timothy Byrne, MD
- Recruiting
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Tracy Spirk
Ramzi Khalil, MD
- Recruiting
UPMC Presbyterian
Pittsburgh, Pennsylvania, 15213
Stephanie Shearer
Ibrahim Sultan, MD
- Recruiting
Maine Medical Center
Portland, Maine, 04102
Joanne Burgess
David Butzel, MD
- Recruiting
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Angela Redd
Brandon Jones, MD
- Recruiting
Mayo Clinic
Rochester, Minnesota, 55905
Tricia Conley
Mohamad Alkhouli, MD
- Recruiting
Saint Francis Hospital
Roslyn, New York, 11576
Joan Jennings
George Petrossian, MD
- Recruiting
Sutter Heatlh
Sacramento, California, 95816
Jessica McCall
Pei-Hsiu Huang, MD
- Recruiting
Kaiser Permanente Northern California
Sacramento, California, 95825
Ann Rose Downing
Femi Philip, MD
- Recruiting
CentraCare Heart and Vascular Center
Saint Cloud, Minnesota, 56303
Jennifer Humbert
Thom Dahle, MD
- Recruiting
Methodist Hospital
San Antonio, Texas, 78229
Abigail Eckenrode
Devang Patel, MD
- Recruiting
Providence Heart Institute (Providence Sacred Heart)
Spokane, Washington, 99204
Nicole McConnell
Brydan Curtis, MD
- Recruiting
Stanford Hospital & Clinics
Stanford, California, 94305
Ayesha Zaina
Anushka Marathe
- Recruiting
Tampa General/USF
Tampa, Florida, 33606
Mia Eifrid
Hiram Bezerra, MD
- Recruiting
Montefiore Medical Center
The Bronx, New York, 10467
Tammy Rodriguez Guzman
Mohamed Azeem Latib, MD
- Recruiting
Los Robles Regional Medical Center
Thousand Oaks, California, 91360
Mane Arabyan
Greg Fontana, MD
- Withdrawn
Tucson Medical Center
Tucson, Arizona, 85712
- Recruiting
MedStar Washington Medical Center
Washington D.C., District of Columbia, 20010
Erin Collins
Ron Waksman, MD
- Recruiting
Ascension Via Christi St. Francis
Wichita, Kansas, 67214
Meredith Thunberg
Bassem Chehab, MD
- Recruiting
Astrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157
Hollie B Davis
Peter Belford, MD
- Recruiting
Lankenau Medical Center
Wynnewood, Pennsylvania, 19096
Eunita Chandardat
Basel Ramlawi, MD
About this study
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).
Read the detailed description
Primary Objectives:
- To determine the acute and long-term outcomes of redo TAVR for the treatment of BVF affecting TAVs
- To determine the factors which are associated with the acute and long-term outcomes of redo TAVR
- Conditions
- Aortic Stenosis
- Being tested
- Medtronic TAV, Edwards TAV
- Medical subject headings
- Aortic Valve Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Medtronic TAVDevice
Medtronic TAV where commercially available
Edwards TAVDevice
Edwards TAV where commercially available.
| Study group | Role | What they receive |
|---|---|---|
| Medtronic Transcatheter Aortic Valves (TAV) or Edwards Transcatheter Aortic Valves (TAV) | Subjects will receive either a Medtronic TAV or Edwards TAV Receives: Device: Medtronic TAV; Device: Edwards TAV |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Outcome Measure
30-day redo TAVR success defined as correct positioning of a single redo prosthetic heart valve into the proper anatomic location, intended performance of the valve (mean gradient <20mmHg, peak velocity <3 m/s, Doppler velocity index (DVI) ≥0.25, aortic regurgitation (AR) < moderate), and freedom from all-cause mortality, coronary obstruction, unplanned coronary revascularization, and surgery or intervention related to the device
Measured: Early (30-days)
Primary Outcome Measure
a composite endpoint of 1-year freedom from all-cause mortality, all stroke, or any re-hospitalization for valve or redo TAVR procedure-related causes
Measured: Late (1-year)
Secondary outcomes (13)
Valve Academic Research Consortium (VARC) 3 technical success (at exit from procedure room)
(VARC) 3 technical success (at exit from procedure room)
Measured: Time of procedure
VARC 3 30-day device success
30-day device success
Measured: 30-Day
VARC 3 30-day early safety
30-day early safety
Measured: 30-Day
Peak and mean invasive gradient post-procedure
Peak and mean invasive gradient will be measured in mmHg
Measured: Time of procedure
In-hospital clinical outcomes
Percentage of all participants with all-cause mortality, all stroke, Myocardial infarction (MI), Coronary artery obstruction, Unplanned Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG), Bleeding (VARC 3 type 1-4), Major and Minor vascular and access-related complications, Cardiac structural complications, Permanent pacemaker implantation (PPI), Acute Kidney Injury (AKI) stage 1-4, Endocarditis, and Valve Thrombosis.
Measured: Treatment up to 7 days (or until patient is discharged from the hospital if later than 7 days)
Clinical outcomes at 30 days, 1-year, and annually thereafter
All-cause mortality, All stroke, Myocardial infarction (MI), Coronary artery obstruction, Bleeding (VARC 3 type 1-4), Major and Minor vascular and access-related complications, Cardiac structural complications, Permanent pacemaker implantation (PPI), Acute Kidney Injury (AKI) stage 1-4, Endocarditis, Valve Thrombosis, Any rehospitalization and re-intervention.
Measured: 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.
Bioprosthetic Valve Dysfunction (BVD) at the final required follow-up visit
Intrinsic permanent changes to the prosthetic valve, including wear and tear, leaflet disruption, flail leaflet, leaflet fibrosis and/or calcification, or strut fracture or deformation
Measured: 5 year
Bioprosthetic Valve Failure (BVF) at the final required follow-up visit
Any bioprosthetic valve dysfunction associated with clinically expressive criteria (new-onset or worsening symptoms, left ventricle dilation/hypertrophy/dysfunction, or pulmonary hypertension) or irreversible Stage 3 Hemodynamic Valve Deterioration (HVD) or Aortic valve reoperation or re-intervention, or Valve-related death.
Measured: Through study completion or Up to 5-years
Echocardiographic assessment pre-discharge or at 30 days, 1-year, and annually thereafter
Left ventricular ejection fraction, mean gradient across aortic valve, effective orifice area, effective orifice area index, patient-prosthesis mismatch, Doppler Velocity Index, total aortic regurgitation, paravalvular aortic regurgitation, and transvalvular aortic regurgitation.
Measured: After the procedure and prior to discharge from the hospital, at 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.
Evaluate coronary accessibility (e.g., commissural alignment, valve to valve alignment, etc.) based on Computed Tomography (CT) at either pre-discharge or 30 days
Evaluate coronary accessibility
Measured: Up to 30 days
New York Heart Association (NYHA) classification at pre-discharge, 30 days, 1-year, and annually thereafter
New York Heart Association (NYHA) classification
Measured: After the procedure and prior to discharge from the hospital, at 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.
KCCQ Quality of life (QoL) assessments at 30 days, 1-year, and annually thereafter
QoL: KCCQ assessment
Measured: At 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.
EQ5D Quality of life (QoL) assessments at 30 days, 1-year, and annually thereafter
QoL: EQ5D assessment
Measured: At 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2025
- Study start6 Feb 2025
- Primary completionNov 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aortic StenosisStudies of the same condition, open and under way.
- More trials run by Medtronic CardiovascularThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 225 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medtronic Cardiovascular
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Gregory Fontana, MD, Study chair, Los Robles Regional Medical CenterGuilherme Attizzani, MD, Principal investigator, UH, Cleveland Medical CenterBasel Ramlawi, Principal investigator, Lankenau Heart Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06777368
- Sponsor's protocol ID
- MDT23040EVR015
- Acronym
- RESTORE
- Status last verified
- Sep 2026
- First submitted
- 17 Dec 2024
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
- ClinicalTrials.gov ID
- NCT06777368
- Acronym / sponsor ID
- RESTORE / MDT23040EVR015
- Conditions
- Aortic Stenosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 225 participants (estimated)
- Lead sponsor
- Medtronic CardiovascularIndustry (pharma, biotech, devices)
- Study start
- 6 Feb 2025 (actual)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 15 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).
Detailed description
Primary Objectives:
- To determine the acute and long-term outcomes of redo TAVR for the treatment of BVF affecting TAVs
- To determine the factors which are associated with the acute and long-term outcomes of redo TAVR
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Medtronic Transcatheter Aortic Valves (TAV) or Edwards Transcatheter Aortic Valves (TAV) | – | Device: Medtronic TAV, Device: Edwards TAVSubjects will receive either a Medtronic TAV or Edwards TAV |
Who may qualify
- Ages
- 18 to 105 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population includes patients with symptomatic heart disease due to BVF affecting TAVs and requiring redo TAVR.
Key inclusion criteria (1 listed)
- BVF of a TAV (either Medtronic or Edwards) requiring redo TAVR
Key exclusion criteria (6 listed)
- BVF due solely to paravalvular regurgitation
- Active endocarditis
- Untreated acute valve thrombosis
- Life-expectancy less than 1-year
- Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Medtronic TAVMedtronic TAV where commercially available | Device | Medtronic Transcatheter Aortic Valves (TAV) or Edwards Transcatheter Aortic Valves (TAV) |
| Edwards TAVEdwards TAV where commercially available. | Device | Medtronic Transcatheter Aortic Valves (TAV) or Edwards Transcatheter Aortic Valves (TAV) |
Primary outcome
Primary Outcome Measure
Time frame: Early (30-days)
30-day redo TAVR success defined as correct positioning of a single redo prosthetic heart valve into the proper anatomic location, intended performance of the valve (mean gradient <20mmHg, peak velocity <3 m/s, Doppler velocity index (DVI) ≥0.25, aortic regurgitation (AR) < moderate), and freedom from all-cause mortality, coronary obstruction, unplanned coronary revascularization, and surgery or intervention related to the device
Primary Outcome Measure
Time frame: Late (1-year)
a composite endpoint of 1-year freedom from all-cause mortality, all stroke, or any re-hospitalization for valve or redo TAVR procedure-related causes
13 secondary outcomes
Valve Academic Research Consortium (VARC) 3 technical success (at exit from procedure room)
Time frame: Time of procedure
VARC 3 30-day device success
Time frame: 30-Day
VARC 3 30-day early safety
Time frame: 30-Day
Peak and mean invasive gradient post-procedure
Time frame: Time of procedure
In-hospital clinical outcomes
Time frame: Treatment up to 7 days (or until patient is discharged from the hospital if later than 7 days)
Clinical outcomes at 30 days, 1-year, and annually thereafter
Time frame: 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.
Bioprosthetic Valve Dysfunction (BVD) at the final required follow-up visit
Time frame: 5 year
Bioprosthetic Valve Failure (BVF) at the final required follow-up visit
Time frame: Through study completion or Up to 5-years
Echocardiographic assessment pre-discharge or at 30 days, 1-year, and annually thereafter
Time frame: After the procedure and prior to discharge from the hospital, at 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.
Evaluate coronary accessibility (e.g., commissural alignment, valve to valve alignment, etc.) based on Computed Tomography (CT) at either pre-discharge or 30 days
Time frame: Up to 30 days
New York Heart Association (NYHA) classification at pre-discharge, 30 days, 1-year, and annually thereafter
Time frame: After the procedure and prior to discharge from the hospital, at 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.
KCCQ Quality of life (QoL) assessments at 30 days, 1-year, and annually thereafter
Time frame: At 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.
EQ5D Quality of life (QoL) assessments at 30 days, 1-year, and annually thereafter
Time frame: At 30 days, at 1 year, at 2 years, at 3 years, at 4 years, and at 5 years.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Aortic Stenosis
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Not yet recruiting
Human Experimental Models of Pain (HEMP)
Acute Pain
Active, not recruitingObservational study
Intravascular Lithotripsy in High Risk Calcified Iliac Anatomy for Transfemoral TAVR
Iliac Disease, Aortic Valve Stenosis
Not yet recruiting
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
Recruiting
Exercise and Diet Supplements for Older Patients Undergoing TAVI: the IRON-TAVI Trial
Aortic Stenosis Disease, Aortic Stenosis Symptomatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gregory Fontana, MD study chair
Los Robles Regional Medical Center
Guilherme Attizzani, MD principal investigator
UH, Cleveland Medical Center
Basel Ramlawi principal investigator
Lankenau Heart Institute
71 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Aortic Stenosis, run by Medtronic Cardiovascular at 71 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 71 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact RESTORE Study Clinical Team (763 514 4000, RS.RESTORESTUDY@medtronic.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Outcome Measure (time frame: Early (30-days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.